Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
Clinical Trials Related to Pomalidomide
Related studies linked through entity extraction aliases.
Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Status
- RECRUITING
- Phase
- PHASE3
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- NA
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Status
- RECRUITING
- Phase
- PHASE3
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
- Status
- COMPLETED
- Phase
- N/A